QDENGA Dengue Vaccine Approved in India: New Phase in Disease Fight
India has approved QDENGA, a new dengue vaccine, marking a significant step in the country's efforts to combat the mosquito-borne disease.
Source: GNews India BiotechIndia's drug regulator has approved QDENGA, a dengue vaccine developed by Takeda Pharmaceutical Company Limited. This approval allows the vaccine to be used in India, offering a new tool in the fight against dengue fever. QDENGA is a live-attenuated tetravalent vaccine, meaning it targets all four serotypes of the dengue virus. It is approved for individuals aged four years and older, regardless of their previous dengue exposure. The vaccine has shown efficacy in clinical trials, reducing the risk of symptomatic dengue and severe dengue cases. This approval is expected to strengthen India's public health response to dengue, a disease that poses a significant burden on the healthcare system annually. The introduction of QDENGA could help reduce hospitalizations and fatalities associated with dengue.
This approval is crucial for exam aspirants studying Science & Technology and Public Health (UPSC GS Paper III, SSC General Awareness). It highlights advancements in vaccine development and India's strategy for disease control. Understanding the type of vaccine (live-attenuated tetravalent) and its target disease (dengue) is important. It also connects to topics like disease burden, public health initiatives, and the role of drug regulators in India.
- QDENGA is a dengue vaccine developed by Takeda Pharmaceutical Company Limited.
- It is a live-attenuated tetravalent vaccine, targeting all four dengue virus serotypes.
- The vaccine is approved for individuals aged four years and older.
- India's drug regulator granted the approval for QDENGA.
- Dengue is a mosquito-borne viral disease prevalent in tropical and subtropical regions.
- The vaccine aims to reduce symptomatic dengue and severe dengue cases.
QDENGA is a live-attenuated tetravalent vaccine developed by Takeda Pharmaceutical Company Limited. It is designed to protect against dengue fever caused by any of the four dengue virus serotypes. The vaccine is administered in two doses, three months apart, and is approved for use in individuals aged four years and older.
Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms include high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash. In severe cases, it can lead to dengue hemorrhagic fever, a life-threatening condition. It is transmitted by Aedes aegypti mosquitoes.
A live-attenuated vaccine uses a weakened (attenuated) form of the virus or bacteria that causes a disease. This weakened form can still replicate in the body but does not cause serious illness. It helps the immune system develop a strong and long-lasting response, similar to natural infection, but without the disease risk.
Exams often ask about new vaccines, their types (e.g., live-attenuated, mRNA), and the diseases they target. Focus on the developer, the disease, and the significance for public health.
Remember 'QDENGA' for 'Quad-Dengue' it protects against all four types of dengue.
Frequently Asked Questions
What is QDENGA vaccine and how does it work against dengue?
QDENGA is a live-attenuated tetravalent vaccine developed by Takeda. It contains weakened versions of all four dengue virus serotypes. When administered, it stimulates the immune system to produce antibodies against these serotypes, providing protection against future dengue infections.
Who can receive the QDENGA vaccine in India?
In India, the QDENGA vaccine is approved for individuals aged four years and older. It can be administered regardless of whether the person has had a prior dengue infection, making it suitable for a broader population.
What are the benefits of QDENGA vaccine approval for India?
The approval of QDENGA provides India with a new tool to combat dengue fever, a significant public health challenge. It is expected to help reduce the incidence of symptomatic dengue, severe cases, hospitalizations, and fatalities, thereby easing the burden on the healthcare system.